Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study is a multicenter, randomized, double-blinded, placebo-controlled trial with two parallel arms. The aim of the study is to evaluate whether Chinese herbal medicine Qing Re Huo Xue (QRHX) combined with methotrexate (MTX) might be better than Qing Re Huo Xue placebo combined with MTX for patients with active rheumatoid arthritis (RA).
To compare the efficacy and safety of Chinese herbal medicine Qing Re Huo Xue (QRHX) and methotrexate (MTX) for patients with active rheumatoid arthritis (RA), a multicenter, randomized controlled trial will be conducted. Two hundred and four patients with active RA will be randomly allocated (1:1) to treatment with QRHX 10g bid and MTX 10mg once a week for 24 weeks, or MTX plus QRHX placebo. The primary outcome is the bone marrow edema score in Outcome Measures in Rheumatology Clinical Trials RA MRI Scoring (OMERACT-RAMRIS) at week 24.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Qing Re Huo Xue (QRHX) granule plus methotrexate (MTX) | Experimental | QRHX granule 10g bid and methotrexate (MTX) 10 mg once a week for 24 weeks |
|
| Qing Re Huo Xue (QRHX) granule placebo plus Methotrexate (MTX) | Placebo Comparator | QRHX granule placebo 10g bid plus Methotrexate (MTX) 10mg once a week for 24 weeks |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Qing Re Huo Xue (QRHX) granule | Drug | Qing Re Huo Xue (QRHX) granule 10g bid for 24 weeks |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change in bone marrow edema score from baseline at week 24 in OMERACT RAMRIS | Bone marrow edema score will be assessed by OMERACT-RAMRIS scoring system; minimum value: 0, maximum value: 75; higher scores mean a worse outcome. | week 0, week 24 |
| Measure | Description | Time Frame |
|---|---|---|
| Change in bone erosion score from baseline at week 24 in OMERACT RAMRIS | Bone erosion score will be assessed by OMERACT-RAMRIS scoring system; minimum value: 0, maximum value: 250; higher scores mean a worse outcome. | week 0, week 24 |
| The proportion of participants with no progression in bone marrow edema and bone erosion |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Quan Jiang, M.D | Guang' anmen hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Guang'anmen Hospital, China Academy of Chinese Medical Sciences | Beijing | 100053 | China |
Not provided
Not provided
Not provided
Not provided
Not provided
| Methotrexate | Drug | Oral methotrexate 10 mg per week for 24 weeks. |
|
|
| Qing Re Huo Xue (QRHX) granule placebo | Drug | Qing Re Huo Xue (QRHX) granule placebo 10g bid for 24 weeks |
|
No progression in bone marrow edema and bone erosion at week 24 is defined as change in RAMRIS osteitis/erosion score ≤0. |
| week 24 |
| The proportion of participants achieving ACR response (ACR20, ACR50, ACR70) | The proportion of participants achieving ACR response (ACR20, ACR50, ACR70) | week 4, week 12, week 24 |
| Change in the 28-joint Disease Activity Score in erythrocyte sedimentation rate | The improvement of DAS28-ESR and proportion of subjects achieving remission was completed. The subjects achieving remission will be defined as DAS28-ESR <2.6. | week 0, week 4, week 12, week 24 |
| Change in Clinical Disease Activity Index (CDAI) | The improvement of CDAI and proportion of subjects achieving remission was completed. The subjects achieving remission will be defined as CDAI <2.8. | week0, week4, week 12, week 24 |
| Change in Chinese patient-reported activity index with rheumatoid arthritis (CPRI-RA) | CPRI-RA,The self-rating scale consists of 11 items,Each item was rated 0, 1, 2 and 3 on the scale of asymptomatic to aggravating symptoms, respectively. | week0, week 4, week 12, week 24 |
| Change in Health Assessment Questionnaire Disability Index (HAQ-DI) | The self-rating scale consists of 20 items,Each item was rated 0, 1, 2 and 3 on the scale of asymptomatic to aggravating symptoms, respectively. (range: 0 [best] to 3 [worst]) | week0, week4, week 12, week 24 |
| ID | Term |
|---|---|
| D001172 | Arthritis, Rheumatoid |
| ID | Term |
|---|---|
| D001168 | Arthritis |
| D007592 | Joint Diseases |
| D009140 | Musculoskeletal Diseases |
| D012216 | Rheumatic Diseases |
| D003240 | Connective Tissue Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D008727 | Methotrexate |
| ID | Term |
|---|---|
| D000630 | Aminopterin |
| D011622 | Pterins |
| D011621 | Pteridines |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D006571 | Heterocyclic Compounds |
Not provided
Not provided